
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Case Based Peer Perspectives: Metastatic Castration-Resistant Prostate Cancer
Case: A 69-Year-Old Man With mCRPC Progressing on Therapy
July 2016
H&P:
Treatment:
March 2017
8 months later, patient complained of fatigue and mild back discomfort
Treatment:Enzalutamide
March 2018
April 2018
April 2019
One year later patient presented with increased lower back discomfort causing disruption in daily activity.



